Category Archives: Data Exclusivity

Stakeholder Intervention at 19th RCEP negotiations round- Chalermsak Kittitrakul, network of PLHIV & AIDS, Peoples’ Health Systems Movement, and FTA Watch

Thai CSOs’ comments on the data exclusivity measure in the RCEP given at the stakeholder consultation meeting hosted by the RCEP trade negotiators at Hyderabad, India on July 25, 2017. Good afternoon, trade negotiators of the ASEAN countries and the … Continue reading

Posted in Data Exclusivity, IPR, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

What’s at stake in Hyderabad

By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading

Posted in Data Exclusivity, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

No logic in extending length of patents

Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines   By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Trading away health

By Rohit Malpani, The Hindu | July 23, 2017 Hyderabad, well known as the hub of the Indian pharmaceuticals industry, ranks third globally in terms of its production volume, with a turnover of Rs. 18 billion a year. Most of … Continue reading

Posted in Data Exclusivity, FTA, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Regional Comprehensive Economic Partnership: Boosting trade or extending monopolies for big pharma?

Published: The Huffington Post India By Leena Menghaney, Head—South Asia, Médecins Sans Frontières (MSF) Access Campaign. MÉDECINS SANS FRONTIÈRES (MSF) Officials from the 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal—which includes the ten ASEAN member states, … Continue reading

Posted in Data Exclusivity, FTA, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

A Trade Deal Could Hit Affordable & Generic Medicines in India. Here’s What You Need to Know.

If accepted the trade deal measures will delay access to affordable medicines by restricting generic competition and maintaining monopoly pricing. Published: The Better India Officials from the sixteen countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal – which … Continue reading

Posted in Data Exclusivity, FTA, Generic competition, Generics, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Out-of-Out-of-Sight RCEP Negotiations Threaten Public Health and Access to Medicines

Although the draft text of the RCEP agreement is not public, leaked documents show that the deal could undermine India’s patent system. Source: The Wire | July 25, 2017 This week, officials from 16 countries will gather in Hyderabad’s International Convention Centre … Continue reading

Posted in Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment